• In late August 2025, Veracyte and University College London announced in Cell that the Decipher Prostate Genomic Classifier can predict which metastatic prostate cancer patients will benefit from docetaxel chemotherapy, while Veracyte also achieved full enrollment in its nightINGALE trial for the Percepta Nasal Swab lung cancer test.
• These developments highlight Veracyte’s ongoing efforts to personalize cancer treatment decisions and expand the clinical utility of its genomic diagnostic portfolio.
• We'll explore how publication of first-in-kind clinical evidence for Decipher Prostate may influence Veracyte's growth outlook and competitive positioning.

We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Veracyte Investment Narrative Recap

Veracyte shareholders are essentially buying into the company's ability to expand the clinical and commercial reach of its advanced diagnostics portfolio, especially Decipher Prostate, while defending against reimbursement, competition, and technology risks. The recent Cell publication could help accelerate Decipher Prostate’s adoption in metastatic prostate cancer and further entrench it as a core revenue driver, but does not materially shift the short-term risk from high revenue concentration. In the near term, the developments primarily reinforce, but do not fundamentally alter, the central catalysts and vulnerabilities for the business.

Among recent announcements, the STAMPEDE trial results published with University College London are the most closely aligned with the company's present catalysts. Clinical validation from a large, randomized study directly strengthens the case for wider clinician and payer uptake of Decipher Prostate, supporting both reimbursement arguments and expansion into new patient segments.

However, investors should also be aware that, by contrast, concentrated dependence on Decipher and Afirma as revenue sources means Veracyte remains exposed to shifts in reimbursement policy or emerging competitors...

Veracyte's outlook anticipates $629.2 million in revenue and $121.9 million in earnings by 2028. This projection is based on a 9.5% annual revenue growth rate and forecasts an earnings increase of $95.6 million from the current $26.3 million level.

Uncover how Veracyte's forecasts yield a $39.75 fair value, a 31% upside to its current price.

Exploring Other Perspectives

Six different Simply Wall St Community members put Veracyte’s fair value between US$24.31 and US$84.40 per share. Opinions vary widely as the company’s revenue growth and clinical momentum compete with ongoing risks tied to product concentration and reimbursement, explore these competing viewpoints.

Explore 6 other fair value estimates on Veracyte - why the stock might be worth 20% less than the current price!

Build Your Own Veracyte Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Veracyte research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Veracyte research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Veracyte's overall financial health at a glance.

Interested In Other Possibilities?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.